Quick answer
What is Eloralintide?
Built from index records dated 2026-10-09 to 2026-10-13 Compiled by an automated pipeline, checked by The Peptide Observer editorial desk. No qualified clinical reviewer. How this site works
Eloralintide is a peptide, grouped on this site under Amylin and amylin receptor agonists, and the 7 research records kept here are 3 from trials in people and 4 that do not state what kind of study it is.
The literature search returned 10 records. This site keeps 7 of them, which is 70 per cent of what came back.
What it is
This site puts it in the Amylin and amylin receptor agonists group.
A selective, long-acting amylin receptor agonist, per the retrieved records.[1, 2]
Stated in the titles of the cited 2025 Lancet and 2026 Diabetes, Obesity and Metabolism papers.
What kind of records
Several of the records kept here are trials in people.
That sentence is produced by counting, not by reading. What was counted: 3 of 7 indexed records are interventional human trials by their own assigned publication type.
What this does not settle
- What it does in a body. Counting records is not reading them, and nothing here has been read in full.
- Whether it causes harm. No adverse-effect row was taken from any source for this entry.
- How long it lasts. No pharmacokinetics source was retrieved for this entry.
- What the other 3 retrieved records say. They are not in this index.
The longer explanation
Where this comes from
The records cited above, in full.
- Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet (London, England) (2025). pmid:41207310
- Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. Diabetes, obesity & metabolism (2026). pmid:41559929